- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01653691
Laser Therapy for Treating Hypertrophic Burn Scars in Children (LaserTherapy)
July 30, 2012 updated by: Mattias Donelan, Massachusetts General Hospital
Tunable-Dye Laser Therapy to Ameliorate Hypertrophic Scarring in Burned Children
Pulse-dye laser therapy has been used to treat the redness, tightness and discomfort of hypertrophic scars resulting from burn injuries.
To date the effectiveness of laser therapy on children's burned scars has not been measured.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
In this study we hope to answer an important question in pediatric burn care: what are the techniques whereby tunable-dye laser neo-vessel ablation is optimally employed to ameliorate hypertrophic scars resulting from burn injuries in children?
Hypertrophic scarring is considered an adverse wound healing event that results in abnormal scar formation.
This scarring process is associated with pruritis and discomfort and can interfere with function and aesthetics.
Topical creams, massage, stretching and pressure are used as standard treatments of burn scar formation.
With the child serving as their own control, we want to objectively measure the impact of PDL on burn scars in children.
Variables of timing of application, duration and number of sessions will all be collected.
Study Type
Interventional
Enrollment (Anticipated)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Martha Lydon, RN,BS
- Phone Number: 617-371-4808
- Email: mlydon@shrinenet.org
Study Contact Backup
- Name: Michelle I Hinson, RN
- Phone Number: 617-371-4809
- Email: mhinson@shrinenet.org
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229-3095
- Shriners Hospitals for Children
-
Contact:
- Kevin Bailey, MD
- Phone Number: 513-872-6000
- Email: kbailey@shrinenet.org
-
Contact:
- Richard Kagan, MD
- Phone Number: 513-872-6000
- Email: rkagan@shrinenet.org
-
Principal Investigator:
- Kevin Bailey, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
9 years to 21 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- subjects 9 years and older to 21 years of age or younger with a second degree burn with erythema and the potential for hypertrophic scarring to the thigh and or trunk.
- subject is clinically stable within 3 months of the burn injury.
- burn size of at least 15cm2 and able to be divided into equivalent halves (divided along line of tension). Equivalent orientation distance from mobil joint with regard to history,physical findings, proximity to tension producing forces and orientation.
- subjects in acute phase of burn injury generally less than one year from the time of the burn injury at 2-3 months post burn when deemed appropriate for pressure therapy, and have been evaluated as an appropriate candidate by a surgeon involved in this study for inclusion.
- subjects can be included up to one year post burn if referred from another treatment facility.
- no skin conditions that could potentially have an adverse effect on wound healing
- all race/ethnic groups
- children/guardians or significant others ability to speak English or Spanish and respond to study questionnaires.
Exclusion Criteria:
- subjects less than 9 years old as this age group is more fragile.
- subjects with no second degree burn to thigh and or trunk
- subjects with chemical burns
- subjects at low risk for hypertrophic scaring (wounds that demonstrate fading erythema at 9-12 weeks and wounds that are healed at less than 3 weeks are at low risk for hypertrophic scaring). Vancouver scar scale pigmentation rating of 0 or 1, vascularity rating of 0 or 1.
- TBSA greater than 50% as massive burns will confound results.
- potential life threatening injuries which would confound the effects of laser treatment and complicate sequential administration of therapy (e.g. shock,sepsis,inhalation therapies, brain injury).
- subjects with other inclusion criteria not met and evaluation by surgeon negative for inclusion in study.
- children/guardians or significant others inability to speak English or Spanish and respond to questionnaires.
- SUBJECTS WITH DOCUMENTED HYPERSENSITIVITY/ALLERGY TO AQUAPHOR,LIDOCAINE OR ANY OF THEIR COMPONENTS.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Pulse Dye Laser, burn scars
A scar will be located on the study subject's torso or thigh and divided in half.
Some subjects will receive laser to both sides of their scar, while others will not receive any intervention to one side and laser to the other side.
Each side will be evaluated during outpatient visits.
12 months after treatment is completed, 2 burn experts will rate each side of the scar without knowing its treatment.
|
Laser therapy will be applied to either one half or both halves of the subject's burn scar.
Laser will be re-applied every 4-6 weeks for a total of 3 administrations.
Other Names:
|
Sham Comparator: No treatment to half of scar
A scar on the child's torso or thigh will be divided in half.
One side will receive laser treatment and the other half will receive laser or sham treatment.
|
No treatment to one side of subject's scar.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Matching Assessment of Scars and Photographs
Time Frame: 12 months after the first laser procedure is completed
|
This scar assessment tool uses a set of reference photographs, a numeric scale, and location technique to measure change over time of a burn scar.
This tool will assist us in determining the comparative merits of laser treatments.
It is portable and inexpensive.
|
12 months after the first laser procedure is completed
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Burn Outcomes Questionnaire
Time Frame: Baseline completion after enrollment and again at 1st,2nd, 3rd, 4th,5th and 6th outpatient visits.
|
The ABA/SHC Burn Outcomes Questionnaires are burn and age specific.
Questions include those about itch, appearance and function; all elements of daily life that may be compromised by hypertrophic scars.
|
Baseline completion after enrollment and again at 1st,2nd, 3rd, 4th,5th and 6th outpatient visits.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Matthias Donelan, MD, Shriners Hospitals for Children-Boston MA USA
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2012
Primary Completion (Anticipated)
March 1, 2014
Study Completion (Anticipated)
January 1, 2015
Study Registration Dates
First Submitted
July 27, 2012
First Submitted That Met QC Criteria
July 30, 2012
First Posted (Estimate)
July 31, 2012
Study Record Updates
Last Update Posted (Estimate)
July 31, 2012
Last Update Submitted That Met QC Criteria
July 30, 2012
Last Verified
July 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010-P-002148
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burn Scars
-
Bispebjerg HospitalCompleted
-
Castle Creek Biosciences, LLC.TerminatedRestrictive Burn ScarsUnited States
-
Castle Creek Biosciences, LLC.WithdrawnRestrictive Burn Scars of Joint AreaUnited States
-
Catalysis SLCompleted
-
Massachusetts General HospitalUnited States Department of Defense; Shriners Hospitals for ChildrenCompleted
-
Association of Dutch Burn CentresCompletedBurns | ScarsNetherlands
-
Dr.dr.Irma Bernadette, SpKK (K)Not yet recruitingBurn Scar | Scars, HypertrophicIndonesia
-
IBSA Farmaceutici Italia SrlDerming SRLRecruitingAcne Scars - Mixed Atrophic and Hypertrophic | Ice Pick Scars | Rolling Scars | Boxcar ScarsItaly
-
University of ZurichUniversity Hospital, ZürichCompletedScars | Burn Injury | Soft Tissue Injury | Skin Necrosis | Congenital Giant Nevus | Skin TumorsSwitzerland
-
Medstar Health Research InstituteLatham FundRecruitingBurn Scar | Cicatrix | Scars | Cicatrix, Hypertrophic | Pigmentation Disorder | Scarring | Hypopigmented Skin | Hypopigmented Scar | Burns LaserUnited States
Clinical Trials on Pulse-Dye Laser
-
Northwestern UniversityCompleted
-
The Metis FoundationUnited States Army Institute of Surgical ResearchCompletedHypertrophic ScarUnited States
-
Henry Ford Health SystemAmerican Academy of Cosmetic SurgeryCompletedPost Surgical ScarsUnited States
-
University of California, DavisWithdrawn
-
Cutera Inc.CompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaUnited States
-
Boston UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)Completed
-
Taipei Medical University WanFang HospitalTerminated
-
Northwestern UniversityEnrolling by invitation
-
University of California, IrvineBeckman Laser Institute University of California Irvine; Candela CorporationCompleted